{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:11:45Z","timestamp":1790723505370,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jconrel.2020.04.002","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T20:29:33Z","timestamp":1586464173000},"page":"83-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Guidelines for the experimental design of pharmacokinetic studies with nanomaterials in preclinical animal models"],"prefix":"10.1016","volume":"323","author":[{"given":"Michael S.","family":"Valic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.04.002_bb0005","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-11-2938","article-title":"Best practices in cancer nanotechnology: Perspective from NCI nanotechnology alliance","volume":"18","author":"Zamboni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0010","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","article-title":"Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective","volume":"52","author":"Moghimi","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41467-017-00600-w","article-title":"Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0025","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1021\/acsnano.9b01383","article-title":"Elimination pathways of nanoparticles","volume":"13","author":"Poon","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/acsnano.5b05999","article-title":"Tumor presence induces global immune changes and enhances nanoparticle clearance","volume":"10","author":"Kai","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2125.1988.tb03318.x","article-title":"Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)","volume":"25","author":"Prentis","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0040","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","article-title":"Clinical biomarkers in drug discovery and development","volume":"2","author":"Frank","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0045","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines - lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0050","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/clpt.2012.12","article-title":"Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents","volume":"91","author":"Caron","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrclinonc.2014.40","article-title":"Determining the optimal dose in the development of anticancer agents","volume":"11","author":"Mathijssen","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.06.008","article-title":"Pharmacokinetics variability: why nanoparticles are not just magic-bullets in oncology","volume":"129","author":"Rodallec","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/acs.accounts.6b00629","article-title":"Nanomedicine 2.0","volume":"50","author":"Chan","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01063558","article-title":"Evaluation of population (NONMEM) pharmacokinetic parameter estimates","volume":"18","author":"Vozeh","year":"1990","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1991.tb03971.x","article-title":"Population pharmacokinetics: theory and practice","volume":"32","author":"Aarons","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0080","first-page":"263","article-title":"Application of sparse sampling approaches in rodent toxicokinetics: a prospective view","volume":"28","author":"Van Bree","year":"1994","journal-title":"Ther Innov Regul Sci."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10601339509079574","article-title":"Review of methods in population pharmacokinetics","volume":"12","author":"Carter","year":"1995","journal-title":"Clin. Res. Regul. Aff."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/019262339502300211","article-title":"Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies","volume":"23","author":"Dahlem","year":"1995","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ilar\/ilw023","article-title":"Balancing blood sample volume with 3Rs: implementation and best practices for small molecule toxicokinetic assessments in rats","volume":"57","author":"Harstad","year":"2016","journal-title":"ILAR J."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0100","first-page":"957","article-title":"Pharmacokinetic theory of cassette dosing in drug discovery screening","volume":"29","author":"White","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0105","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S1359-6446(04)03137-X","article-title":"Whatever happened to cassette-dosing pharmacokinetics?","volume":"9","author":"Manitpisitkul","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0110","series-title":"Princ Methods Toxicol Fifth Ed","first-page":"1223","article-title":"Short-term, subchronic and chronic toxicology studies","author":"Wilson","year":"2007"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF02353461","article-title":"Analysis of animal pharmacokinetic data: performance of the one point per animal design","volume":"23","author":"Ette","year":"1995","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10601339409005295","article-title":"Influence of inter-animal variability on the estimation of population pharmacokinetic parameters in preclinical studies","volume":"11","author":"Ette","year":"1994","journal-title":"Clin. Res. Regul. Aff."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0125","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF01070904","article-title":"Optimal sampling times for pharmacokinetic experiments","volume":"9","author":"D\u2019Argenio","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0130","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00280-010-1406-x","article-title":"Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?","volume":"66","author":"Mamidi","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0135","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1023\/A:1016079228995","article-title":"Serial versus sparse sampling in toxicokinetic studies","volume":"13","author":"Tse","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0140","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s11095-013-1286-y","article-title":"One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics","volume":"31","author":"Joyce","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0145","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/02664763.2013.780234","article-title":"Statistical considerations in bioequivalence of two area under the concentration\u2013time curves obtained from serial sampling data","volume":"40","author":"Hua","year":"2013","journal-title":"J. Appl. Stat."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1081\/BIP-200040853","article-title":"Optimal population designs for PK models with serial sampling","volume":"15","author":"Gagnon","year":"2004","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jat.727","article-title":"A good practice guide to the administration of substances and removal of blood, including routes and volumes","volume":"21","author":"Diehl","year":"2001","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/0023677011911345","article-title":"Refining procedures for the administration of substances","volume":"35","author":"Morton","year":"2001","journal-title":"Lab. Anim."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.05.049","article-title":"Developing early formulations: practice and perspective","volume":"341","author":"Li","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0170","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41565-018-0273-1","article-title":"Roadmap and strategy for overcoming infusion reactions to nanomedicines","volume":"13","author":"Szebeni","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0175","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.drudis.2017.11.006","article-title":"Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection\/infusion reactions","volume":"23","author":"Moghimi","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0180","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/fon.10.100","article-title":"Intraperitoneal therapy for peritoneal cancer","volume":"6","author":"Lu","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0185","first-page":"600","article-title":"Administration of substances to laboratory animals: routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/0976-500X.72350","article-title":"Blood sample collection in small laboratory animals","volume":"1","author":"Parasuraman","year":"2010","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0195","article-title":"Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol","volume":"6","author":"Park","year":"2018","journal-title":"Phys. Rep."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0031-9384(84)90018-0","article-title":"Chronic vascular catheterization in the rat: comparison of three techniques","volume":"33","author":"Yoburn","year":"1984","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0205","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-198917030-00004","article-title":"The phenomenon and rationale of marked dependence of drug concentration on blood sampling site","volume":"17","author":"Chiou","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0210","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/jps.2600731128","article-title":"Influence of mode of intravenous administration and blood sample collection on rat pharmacokinetic data","volume":"73","author":"Tse","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ilar.31.4.5","article-title":"Biological effects of blood loss: implications for sampling volumes and techniques * commentary: H. Richard Adams","volume":"31","author":"McGuill","year":"1989","journal-title":"ILAR J."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0220","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1021\/mp200626j","article-title":"Blood\u2013nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties","volume":"9","author":"Shah","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0225","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1039\/C4CC07644C","article-title":"Nanoparticle\u2013blood interactions: the implications on solid tumour targeting","volume":"51","author":"Lazarovits","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0230","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1742-7843.2009.00533.x","article-title":"Optimal design of pharmacokinetic studies","volume":"106","author":"Aarons","year":"2010","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0235","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1002\/sim.2512","article-title":"Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments","volume":"25","author":"Graham","year":"2006","journal-title":"Stat. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/19466315.2018.1458647","article-title":"Optimal designs for non-compartmental analysis of pharmacokinetic studies","volume":"10","author":"Barnett","year":"2018","journal-title":"Stat Biopharm Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0245","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/10543400701514080","article-title":"Population pharmacokinetic measures, Their estimation and selection of sampling times","volume":"17","author":"Fedorov","year":"2007","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0250","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.7150\/thno.34509","article-title":"Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans","volume":"9","author":"Valic","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/laban1006-49","article-title":"Animal reuse: balancing scientific integrity and animal welfare","volume":"35","author":"Kovalcsik","year":"2006","journal-title":"Lab Anim (NY)."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0260","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0265","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-3565(24)29419-2","article-title":"Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection","volume":"298","author":"Laverman","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0275","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0285","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1021\/bm100754e","article-title":"Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers","volume":"11","author":"Ishihara","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0290","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0295","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics3010001","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"3","author":"Ichihara","year":"2010","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0305","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-009-9943-x","article-title":"Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles","volume":"26","author":"Ishihara","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0310","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s11095-012-0934-y","article-title":"Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug","volume":"30","author":"Saadati","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0315","series-title":"Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, Rockville, MD","author":"Food and Drug Administration Center for Drug Evaluation and Research","year":"2010"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0320","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1061186021000072447","article-title":"Dose dependency of Pharmacokinetics and therapeutic efficacy of Pegylated liposomal doxorubicin (DOXIL) in murine models","volume":"10","author":"Gabizon","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0325","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1124\/jpet.103.053413","article-title":"Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity","volume":"306","author":"Charrois","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0330","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0169-409X(96)00476-0","article-title":"Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals","volume":"24","author":"Gabizon","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0335","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0009-9236(97)90162-4","article-title":"Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi\u2019s sarcoma","volume":"61","author":"Amantea","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0340","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0345","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/BF02353484","article-title":"On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data","volume":"24","author":"Sun","year":"1996","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0350","series-title":"Non-Biological Complex Drugs Sci Regul Landsc","first-page":"261","article-title":"NBCD pharmacokinetics and bioanalytical methods to measure drug release","author":"Ambardekar","year":"2015"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0355","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1124\/dmd.116.073148","article-title":"When is it important to measure unbound drug in evaluating nanomedicine pharmacokinetics?","volume":"44","author":"Stern","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0360","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17425247.2016.1244187","article-title":"Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures","volume":"14","author":"Ragelle","year":"2017","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0365","first-page":"1","article-title":"Mapping of the available standards against the regulatory needs for nanomedicines","volume":"11","author":"Halamoda-Kenzaoui","year":"2019","journal-title":"Wiley Interdiscip Rev Nanomedicine Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0370","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.trac.2005.07.006","article-title":"Analytical methods for the control of liposomal delivery systems","volume":"25","author":"G\u00f3mez-Hens","year":"2006","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0375","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1007\/s00216-015-8805-0","article-title":"Rapid evaluation of the quantity of drugs encapsulated within nanoparticles by high-performance liquid chromatography in a monolithic silica column","volume":"407","author":"Itoh","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0380","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2010.04.008","article-title":"Translational considerations for cancer nanomedicine","volume":"146","author":"Stern","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0390","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.addr.2018.09.012","article-title":"Animal models for analysis of immunological responses to nanomaterials: challenges and considerations","volume":"136\u2013137","author":"Zamboni","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0395","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.30","article-title":"Capture of stealth nanoparticles by the body\u2019s defences","volume":"18","author":"Moghimi","year":"2001","journal-title":"Crit Rev Ther Drug Carr Syst."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nnm.14.60","article-title":"Predicting the impact of biocorona formation kinetics on interspecies extrapolations of nanoparticle biodistribution modeling","volume":"10","author":"Sahneh","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0405","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10928-011-9213-5","article-title":"Allometric scaling of pegylated liposomal anticancer drugs","volume":"38","author":"Caron","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0410","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acs.molpharmaceut.6b01118","article-title":"Analyzing the potential root causes of variability of pharmacokinetics in preclinical species","volume":"14","author":"Daublain","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0415","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1172\/JCI66895","article-title":"Nanoparticle clearance is governed by Th1\/Th2 immunity and strain background","volume":"123","author":"Jones","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0420","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1158\/1535-7163.MCT-18-0977","article-title":"Mouse strains influence clearance and efficacy of antibody and antibody\u2013drug conjugate via fc\u2013Fc\u03b3R interaction","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0425","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1002\/hep.21060","article-title":"The liver as an immunological organ","volume":"43","author":"Racanelli","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0430","first-page":"1","article-title":"Mechanism of hard-nanomaterial clearance by the liver","volume":"1","author":"Tsoi","year":"2016","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0435","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0192623310373776","article-title":"Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development","volume":"38","author":"Festing","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0440","series-title":"Mouse Model Drug Discov Methods Mol Biol (MIMB, Vol 1438)","first-page":"1","article-title":"Genetically defined strains in drug development and toxicity testing","author":"Festing","year":"2016"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0445","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0450","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/17425255.4.7.871","article-title":"Species selection considerations for preclinical toxicology studies for biotherapeutics","volume":"4","author":"Bussiere","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0455","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0300985811402846","article-title":"Swine as models in biomedical research and toxicology testing","volume":"49","author":"Swindle","year":"2012","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0460","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1158\/1078-0432.CCR-12-3649","article-title":"A review of study designs and outcomes of phase I clinical studies of nanoparticle agents compared with small-molecule anticancer agents","volume":"19","author":"Caron","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0465","doi-asserted-by":"crossref","first-page":"15127","DOI":"10.1073\/pnas.1309566110","article-title":"Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle","volume":"110","author":"Eliasof","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0470","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0475","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a psma-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0480","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/anie.201710584","article-title":"Dose dependencies and biocompatibility of renal clearable gold nanoparticles: from mice to non-human primates","volume":"57","author":"Xu","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0485","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/01926230390175002","article-title":"The common marmoset (Callithrix jacchus) as a model in toxicology","volume":"31","author":"Z\u00fchlke","year":"2003","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0490","doi-asserted-by":"crossref","first-page":"L146","DOI":"10.1152\/ajplung.1999.276.1.L146","article-title":"Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species","volume":"276","author":"Brain","year":"1999","journal-title":"Am J Physiol Cell Mol Physiol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0495","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.drudis.2018.01.025","article-title":"Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?","volume":"23","author":"Szebeni","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1515\/ejnm-2012-0002","article-title":"Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions","volume":"4","author":"Szebeni","year":"2012","journal-title":"Eur J Nanomed."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0505","first-page":"128","article-title":"Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine, nanomedicine nanotechnology","volume":"5","author":"Fent","year":"2009","journal-title":"Biol Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0510","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.taap.2008.12.023","article-title":"Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles","volume":"236","author":"Cho","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0515","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejpb.2011.09.005","article-title":"Effect of surface coating on the biodistribution profile of gold nanoparticles in the rat","volume":"80","author":"Morais","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0520","doi-asserted-by":"crossref","first-page":"1900589","DOI":"10.1002\/smtd.201900589","article-title":"Microphysiological systems: next generation systems for assessing toxicity and therapeutic effects of nanomaterials","volume":"4","author":"Ashammakhi","year":"2020","journal-title":"Small Methods."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0525","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/00498250010021684","article-title":"Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man","volume":"30","author":"Bogaards","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0530","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1020134521778","article-title":"Liposome clearance","volume":"22","author":"Ishida","year":"2002","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0535","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1039\/c2cs15327k","article-title":"Design of polymeric nanoparticles for biomedical delivery applications","volume":"41","author":"Elsabahy","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0540","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/wnan.1304","article-title":"Pharmacokinetics of metallic nanoparticles","volume":"7","author":"Lin","year":"2015","journal-title":"Wiley Interdiscip Rev Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0545","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1056-8719(00)00110-6","article-title":"Present and future in vitro approaches for drug metabolism","volume":"44","author":"Ekins","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0550","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.7150\/thno.4652","article-title":"Image guided biodistribution and pharmacokinetic studies of Theranostics","volume":"2","author":"Ding","year":"2012","journal-title":"Theranostics."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0555","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/acs.chemrev.6b00073","article-title":"Nanomaterials for in vivo imaging","volume":"117","author":"Smith","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0560","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1021\/acssensors.6b00834","article-title":"In vivo biosensing: Progress and perspectives","volume":"2","author":"Rong","year":"2017","journal-title":"ACS Sensors."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0565","doi-asserted-by":"crossref","first-page":"1700262","DOI":"10.1002\/adbi.201700262","article-title":"Molecular fluorescence and photoacoustic imaging in the second near-infrared optical window using organic contrast agents","volume":"2","author":"Jiang","year":"2018","journal-title":"Adv Biosyst."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0570","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00259-013-2685-3","article-title":"The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI","volume":"41","author":"Bernsen","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0575","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2967\/jnumed.108.055442","article-title":"Small-animal SPECT and SPECT\/CT: important tools for preclinical investigation","volume":"49","author":"Franc","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0580","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3109\/03602539709002238","article-title":"The role of positron emission tomography in pharmacokinetic analysis","volume":"29","author":"Fischman","year":"1997","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0585","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2967\/jnumed.111.099382","article-title":"NEMA NU 4-2008 comparison of preclinical PET imaging systems","volume":"53","author":"Goertzen","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0590","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2967\/jnumed.112.111476","article-title":"An evidence-based review of quantitative SPECT imaging and potential clinical applications","volume":"54","author":"Bailey","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0595","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1109\/TMI.2002.1000263","article-title":"Spatiotemporal reconstruction of list-mode PET data","volume":"21","author":"Nichols","year":"2002","journal-title":"IEEE Trans. Med. Imaging"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0600","series-title":"Imaging Drug Discov Early Clin Trials Prog Drug Res","first-page":"279","article-title":"Pharmacokinetic studies with PET","author":"Bergstr\u00f6m","year":"2005"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0605","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ilar.49.1.17","article-title":"Anesthesia and other considerations for in vivo imaging of small animals","volume":"49","author":"Hildebrandt","year":"2008","journal-title":"ILAR J."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0610","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2967\/jnumed.107.041061","article-title":"Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data","volume":"48","author":"Ferl","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0615","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0969-8051(00)00155-4","article-title":"Anatomy of SUV","volume":"27","author":"Huang","year":"2000","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0620","first-page":"1836","article-title":"SUV: standard uptake or silly useless value?","volume":"36","author":"Keyes","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0625","first-page":"1431","article-title":"Understanding the standardized uptake value, its methods, and implications for usage","volume":"45","author":"Thie","year":"2004","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0630","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.nucmedbio.2005.06.012","article-title":"Measurement of input functions in rodents: challenges and solutions","volume":"32","author":"Laforest","year":"2005","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0635","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2967\/jnumed.107.047613","article-title":"Spillover and partial-volume correction for image-derived input functions for small-animal 18F-FDG PET studies","volume":"49","author":"Fang","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0640","first-page":"802","article-title":"Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data","volume":"48","author":"Teo","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0645","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1088\/0031-9155\/50\/13\/001","article-title":"Cardiac PET imaging in mice with simultaneous cardiac and respiratory gating","volume":"50","author":"Yang","year":"2005","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0650","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/ph7040392","article-title":"Radiolabeling of nanoparticles and polymers for PET imaging","volume":"7","author":"Stockhofe","year":"2014","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0655","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/cmmi.1530","article-title":"Radiolabeling approaches of nanoparticles with 99mTc","volume":"8","author":"Psimadas","year":"2013","journal-title":"Contrast Media Mol Imaging."},{"key":"10.1016\/j.jconrel.2020.04.002_bb0660","series-title":"The Molecular Probes Handbook\u2014A Guide to Fluorescent Probes and Labeling Technologies","year":"2010"},{"key":"10.1016\/j.jconrel.2020.04.002_bb0665","series-title":"Guidance for Industry: Developing medical imaging drug and biological products. Part 1: Conducting Safet Assessments, Rockville, MD","author":"Food and Drug Administration Center for Drug Evaluation and Research","year":"2004"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:48:36Z","timestamp":1759160916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920302133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":132,"alternative-id":["S0168365920302133"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines for the experimental design of pharmacokinetic studies with nanomaterials in preclinical animal models","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}